Gemcitabine

製品コードS1714 別名:LY-188011, NSC 613327

Gemcitabine 化学構造

分子量(MW):263.2

Gemcitabine, a nucleic acid synthesis inhibitor, is a very potent and specific deoxycytidine analogue, used as chemotherapy.

サイズ 価格(税別)  
JPY 21580.00
JPY 16102.00

カスタマーフィードバック(4)

  • Mice were administered either vehicle, gemcitabine (120 mg/kg [PaCa2]) or 20 mg/kg of BBI608 i.p. After killing, tumors were collected after 7 or 14 d of treatment, for Paca-2 and FaDu cells, respectively. Single-cell suspensions were obtained after animal killing and sterile removal of tumors. Live cells were then counted and used to measure their ability to form spheres when cultured in cancer stem cell media.

    Proc Natl Acad Sci USA, 2015, 112(6): 1839-44. Gemcitabine purchased from Selleck.

    RNA incorporating drugs induce SG assembly. HeLa cells were treated with the RNA incorporating agents 5-azacytidine (50 uM) and 6-thioguanine (10 uM), or the DNA incorporating agents trifluorothymidine (10 uM) and gemcitabine (100 nM) for 72 h. Subsequently, the cellular localization of the SG marker protein TIAR (green) and the P-body marker protein DCP1 (red) was analyzed. Nuclei were stained with Hoechst. Scale bars represent 20 um.

    Nucleic Acids Res 2014 42(10), 6436-47. Gemcitabine purchased from Selleck.

  • Immunofluorescent analysis of gemcitabine-induced γH2A.X and 53-BP1 focus formation. a, b Immunofluorescence staining of γH2A.X(green), 53-BP1 (red), and nuclei staining with DAPI (blue) in T24 (a) and T24r GEMCI20 (b) cells after the indicated treatments. Scale bar = 50 μm

    J Exp Clin Cancer Res, 2017, 36(1):1. Gemcitabine purchased from Selleck.

    Cells were seeded in 96 well paltes, and then treated with the indicated concentration of Gemcitabine for 48h. Cell survival was measured by a standarad MTT assay.

    Dr. Helen Sadik of Johns Hopkins University. Gemcitabine purchased from Selleck.

製品安全説明書

DNA/RNA Synthesis阻害剤の選択性比較

生物活性

製品説明 Gemcitabine, a nucleic acid synthesis inhibitor, is a very potent and specific deoxycytidine analogue, used as chemotherapy.
体外試験

Gemcitabine results in 50% inhibition of growth in the CCRF-CEM human leukemia cell culture assay with IC50 of 1 ng/ml. Gemcitabine combined with deoxycytidine provides about a 1000-fold decrease in biological activity. [1] Gemcitabine combined with C225 results in additive cytotoxic effects that increased with increasing gemcitabine concentrations in human pancreatic carcinoma L3.6pl cells. [2] Gemcitabine combined with Cisplatin results in synergistic effect in wild-type A2780 and cisplatin-resistant ADDP cells. [3]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV-4-11 M2\wTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTBwMECwOFU5KG6P M{\ySHNCVkeHUh?=
ES4 NUGwZ|ViT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTBwMECwOlU{KG6P M{jrcHNCVkeHUh?=
ACHN NHfvd3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrxPZlKSzVyPUCuNFAxQDh5IH7N M4C0[nNCVkeHUh?=
KYSE-510 Mo\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXjTWM2OD1yLkCwNFk4PSCwTR?= MlLOV2FPT0WU
EW-7 NYPnNlZKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HlOmlEPTB;MD6wNFI2QCCwTR?= M4rMfXNCVkeHUh?=
BFTC-905 NX3LU21ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3T6cWlEPTB;MD6wNFUyPSCwTR?= Ml;xV2FPT0WU
KE-37 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PKbmlEPTB;MD6wNFU3OSCwTR?= M2LjSnNCVkeHUh?=
SBC-5 M1\nVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTBwMEC1O{BvVQ>? MkjaV2FPT0WU
NKM-1 NWDUS4tQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXq4PIc5UUN3ME2wMlAxPzB7IH7N MYnTRW5ITVJ?
RH-1 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW[2NGt{UUN3ME2wMlAxPzF6IH7N NYLySlNmW0GQR1XS
ALL-PO M{i5T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF70bWxKSzVyPUCuNFA5OyCwTR?= NYC5TXdRW0GQR1XS
QIMR-WIL NF3Lc4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXBSlI3UUN3ME2wMlAxQDl2IH7N NF3VdXlUSU6JRWK=
A375 MnK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTBwMEC5PVUhdk1? M4nFfXNCVkeHUh?=
SIG-M5 NWX5RVFtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{X5[mlEPTB;MD6wNVA1KG6P NVLhWJRmW0GQR1XS
KGN MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\s[JhwUUN3ME2wMlAyODhibl2= M2\pVXNCVkeHUh?=
EW-13 MkLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\2TWM2OD1yLkCxNVIhdk1? MUHTRW5ITVJ?
NCI-SNU-1 M{DhO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjzVIhKSzVyPUCuNFE3KG6P M2nVWXNCVkeHUh?=
PSN1 MnW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTBwMEG2OUBvVQ>? NGrOc|hUSU6JRWK=
HUTU-80 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVmzPG84UUN3ME2wMlAyPjZibl2= NHjsXFNUSU6JRWK=
EW-16 Mkn4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYqyT|hUUUN3ME2wMlAzOyCwTR?= M{DyXXNCVkeHUh?=
786-0 MlToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHhPY5CUUN3ME2wMlAzOyCwTR?= Ml2yV2FPT0WU
ES1 M1W3PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrEOZBKSzVyPUCuNFI3QCCwTR?= NEDZd5hUSU6JRWK=
RKO MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HTemlEPTB;MD6wNlc6KG6P NXO4OGdlW0GQR1XS
ESS-1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrrNmJ7UUN3ME2wMlAzQDZibl2= NH3nfHBUSU6JRWK=
SK-UT-1 Mn3yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2P1W2lEPTB;MD6wNlk4KG6P MX7TRW5ITVJ?
LB2241-RCC MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PhcWlEPTB;MD6wN|E5KG6P M2\xSHNCVkeHUh?=
CHL-1 Mn33S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLwTWM2OD1yLkCzNlQhdk1? MX3TRW5ITVJ?
SW1783 NWSwOYV4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXMT|JKSzVyPUCuNFM{PiCwTR?= NFPLOnRUSU6JRWK=
MEL-JUSO M3fINWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXpNYd7UUN3ME2wMlA{QTFibl2= MXPTRW5ITVJ?
HT-29 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjKU4kxUUN3ME2wMlA1OTNibl2= MoXHV2FPT0WU
SNG-M NV3COphDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PtZmlEPTB;MD6wOFI2KG6P M2\Sc3NCVkeHUh?=
TE-15 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF6xc4FKSzVyPUCuNFQ3PCCwTR?= MkDIV2FPT0WU
HOS NYjjdZFjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrwfJBKSzVyPUCuNFQ5KG6P MVjTRW5ITVJ?
BB65-RCC M4XqXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVz4[HhUUUN3ME2wMlA2OTJibl2= NIrXXZRUSU6JRWK=
HCE-4 MnjkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWm3enpEUUN3ME2wMlA2Ojhibl2= M{HNPXNCVkeHUh?=
MHH-ES-1 M1:0XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTBwMEWzNUBvVQ>? NYTQVHMzW0GQR1XS
RPMI-7951 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDIeIRsUUN3ME2wMlA2PDFibl2= M4m4SHNCVkeHUh?=
IST-SL2 M2nBW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\lfoVMUUN3ME2wMlA2QDRibl2= MVvTRW5ITVJ?
CMK MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGi5TlVKSzVyPUCuNFU5PiCwTR?= MmnUV2FPT0WU
GR-ST NFfkbotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfkSphKSzVyPUCuNFU6PSCwTR?= M{OwcnNCVkeHUh?=
NALM-6 NVHO[HZPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTBwME[yNkBvVQ>? NUG2XY1CW0GQR1XS
RPMI-6666 MmHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;GW3BZUUN3ME2wMlA3PTJibl2= MoKyV2FPT0WU
LC-2-ad NY\yWJZST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDUTWM2OD1yLkC2OVMhdk1? NVLSOmc1W0GQR1XS
ARH-77 NWnacIxCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;0V3VKSzVyPUCuNFcyOSCwTR?= MVnTRW5ITVJ?
IST-MEL1 M{\jdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nJWWlEPTB;MD6wO|I3KG6P M2r5UHNCVkeHUh?=
SW1710 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3SyUWlEPTB;MD6wO|UyKG6P M2DQXHNCVkeHUh?=
DEL M4L1W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrtb|lKSzVyPUCuNFg5PyCwTR?= M4q0fHNCVkeHUh?=
AGS NIS5bppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTBwMEmwNkBvVQ>? MX3TRW5ITVJ?
NCI-H2122 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmL1TWM2OD1yLkC5OFYhdk1? MVjTRW5ITVJ?
HSC-4 NFyzW3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3:0eGlEPTB;MD6xNFIhdk1? M{LvbXNCVkeHUh?=
AM-38 M4Gwdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknNTWM2OD1yLkGyNUBvVQ>? MU\TRW5ITVJ?
769-P M4SwNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYP2cHpvUUN3ME2wMlEzOyCwTR?= M4WxR3NCVkeHUh?=
RT-112 NV;QS4lDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\RbGlEPTB;MD6xNlchdk1? NEXiNYZUSU6JRWK=
MCF7 MnfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHT[mhKSzVyPUCuNVM3KG6P NHPacJpUSU6JRWK=
IGROV-1 M1TuOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTBwMUS1JI5O MV\TRW5ITVJ?
OCI-AML2 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3KcFJrUUN3ME2wMlE1PyCwTR?= NInUNFRUSU6JRWK=
NCI-H1299 MmD0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\ibVZKSzVyPUCuNVU4KG6P M4fJVXNCVkeHUh?=
A431 M1myWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPZTWM2OD1yLkG4N{BvVQ>? M{LYZXNCVkeHUh?=
SW982 M3rsN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPMVmRKSzVyPUCuNlE{KG6P NV[1e3RFW0GQR1XS
BB30-HNC NHLVeHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDJbYJ6UUN3ME2wMlI{OSCwTR?= NF3xW5dUSU6JRWK=
ACN NWDyR5hVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3kW|hKSzVyPUCuNlQ1KG6P NFn0blBUSU6JRWK=
647-V MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofNTWM2OD1yLkK0PEBvVQ>? MVPTRW5ITVJ?
SK-PN-DW NFL6[|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrqcJlCUUN3ME2wMlI3PiCwTR?= NIDvdJRUSU6JRWK=
LCLC-97TM1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M372T2lEPTB;MD6yOlchdk1? M1vFO3NCVkeHUh?=
LB1047-RCC MnfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDUOmpKSzVyPUCuNlY6KG6P MWXTRW5ITVJ?
A2780 Moe0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWX5ZphMUUN3ME2wMlI4KG6P NXryeJlvW0GQR1XS
C-33-A M2Kybmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXj2UYp4UUN3ME2wMlI4OyCwTR?= NGnH[3lUSU6JRWK=
NCI-H2228 M1jyXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLjTWM2OD1yLkOxOEBvVQ>? MVHTRW5ITVJ?
TE-5 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LuUmlEPTB;MD6zNVYhdk1? MVTTRW5ITVJ?
HC-1 M2n5Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1H5RmlEPTB;MD6zNlchdk1? NEm3SnlUSU6JRWK=
SK-MES-1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LrZ2lEPTB;MD6zNlghdk1? MYnTRW5ITVJ?
NCI-H1355 Mn[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzkTWM2OD1yLkO4NUBvVQ>? MoPyV2FPT0WU
YKG-1 M1fRUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vqemlEPTB;MD60NVkhdk1? NG\iW29USU6JRWK=
RS4-11 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX[1fGd6UUN3ME2wMlQ{OyCwTR?= NIT1PJRUSU6JRWK=
Daoy NHnqZYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTBwNEW2JI5O M{jqNHNCVkeHUh?=
A3-KAW NIjTOnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4Ho[mlEPTB;MD61OVEhdk1? MVfTRW5ITVJ?
SK-MEL-30 NGfucFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HqNGlEPTB;MD61OVQhdk1? MlHkV2FPT0WU
U031 MmjiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTBwNU[1JI5O NFPRcG9USU6JRWK=
SK-LMS-1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTpTWM2OD1yLkW3PEBvVQ>? NIr0NnJUSU6JRWK=
ES6 M1nuR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HKdmlEPTB;MD61PFYhdk1? NW\KdG13W0GQR1XS
EoL-1-cell M1fYb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkP2TWM2OD1yLk[xOkBvVQ>? NWHUPFdCW0GQR1XS
NCI-H2009 NF\3VWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLMS2JXUUN3ME2wMlYyQSCwTR?= M4ezR3NCVkeHUh?=
A4-Fuk NG\PNFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnyb|VLUUN3ME2wMlYzPiCwTR?= MmWzV2FPT0WU
KYSE-270 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTBwNkO0JI5O MWLTRW5ITVJ?
SK-LU-1 M3jqTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\SeY14UUN3ME2wMlY2PSCwTR?= MmfLV2FPT0WU
SW872 M2HOUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFj4dHNKSzVyPUCuO|Y2KG6P NEXEb5hUSU6JRWK=
ES8 MlG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTBwN{igcm0> MkPkV2FPT0WU
G-402 NHju[5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLHTWM2OD1yLke4OEBvVQ>? NYC3fGN{W0GQR1XS
ATN-1 Mmq4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1S3UGlEPTB;MD64NFchdk1? NFThOFVUSU6JRWK=
DoTc2-4510 M4i3Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnnTWM2OD1yLkmwNUBvVQ>? MVfTRW5ITVJ?
MES-SA MlTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmH3TWM2OD1yLkmwOUBvVQ>? NUX6VXFQW0GQR1XS
SF268 NU\DV3pxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHLUXpFUUN3ME2wMlkzPyCwTR?= NYfXNVcxW0GQR1XS
SF539 NYCzTHVVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\sVmlEPTB;MT6wNkBvVQ>? MoTTV2FPT0WU
NB69 NFTCU4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTFwMEWgcm0> MUDTRW5ITVJ?
8505C NILCXnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jGOWlEPTB;MT6wOkBvVQ>? NGjZO|lUSU6JRWK=
CAL-12T NFv3O4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTFwMEigcm0> M4G1b3NCVkeHUh?=
BHY Ml\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfkdZVKSzVyPUGuNVQhdk1? M2fwPXNCVkeHUh?=
LB647-SCLC NIP6R49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\nW2hrUUN3ME2xMlE5KG6P MonZV2FPT0WU
CAL-62 M3LpRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUT2eo1EUUN3ME2xMlIzKG6P M4HWVnNCVkeHUh?=
MEG-01 M{\6UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTFwMkegcm0> MlrzV2FPT0WU
MG-63 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\sOGlEPTB;MT6zN{BvVQ>? MmfPV2FPT0WU
SW620 NV\5b|l5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjkRnhKSzVyPUGuN|Uhdk1? NWHMV4pWW0GQR1XS
A388 NIXhO4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\ITGlEPTB;MT6zOkBvVQ>? NHTtUJlUSU6JRWK=
BCPAP M4PHNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zqXWlEPTB;MT60OUBvVQ>? NU\4ZnVnW0GQR1XS
P30-OHK NGe2PGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\iTWM2OD1zLkS2JI5O M3TPXHNCVkeHUh?=
Ca9-22 MljKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7OcnBTUUN3ME2xMlU1KG6P NULHXWVYW0GQR1XS
VMRC-RCZ MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjDPW9CUUN3ME2xMlU1KG6P M2DZPXNCVkeHUh?=
LOXIMVI MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TuSmlEPTB;MT62JI5O NVnNWG9bW0GQR1XS
L-540 Mmr6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXCTWM2OD1zLk[gcm0> MUTTRW5ITVJ?
NTERA-S-cl-D1 NULCSldtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTFwNkSgcm0> M1P6THNCVkeHUh?=
MFH-ino NF[zU29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTFwNk[gcm0> M1T4R3NCVkeHUh?=
Calu-6 MnvkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTFwN{Ogcm0> NEHEZWRUSU6JRWK=
HEL NWrjbHlYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYf3XWN2UUN3ME2xMlc6KG6P MWLTRW5ITVJ?
CAL-33 M3;xbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mme1TWM2OD1zLki5JI5O M2DsUnNCVkeHUh?=
HSC-3 NY\ufHFKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTFwOUGgcm0> MkH2V2FPT0WU
KU812 NYjDO2FXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDCVGdKSzVyPUGuPVEhdk1? M3rV[XNCVkeHUh?=
EB2 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGmy[JFKSzVyPUKuNFEhdk1? MYLTRW5ITVJ?
SR NWTocYlGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2e4b2lEPTB;Mj6xNkBvVQ>? Mn\QV2FPT0WU
NCI-H2087 MoOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTJwMUSgcm0> M13OcnNCVkeHUh?=
H4 NFPaZY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPPdo5KSzVyPUKuNVghdk1? Ml\CV2FPT0WU
EW-1 NVyxT4NjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rybGlEPTB;Mj6yNkBvVQ>? NXLselJ1W0GQR1XS
MC-IXC MnTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTJwMk[gcm0> M{P6N3NCVkeHUh?=
NCI-H727 MkLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLrbWZGUUN3ME2yMlUyKG6P MXHTRW5ITVJ?
MRK-nu-1 NH\pRWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPtfXdKSzVyPUKuOVchdk1? NYfLcIVNW0GQR1XS
COLO-668 NYSze|U3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjtTWM2OD1{Lk[2JI5O NHHwTldUSU6JRWK=
CGTH-W-1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3VPIpKSzVyPUKuO|Ihdk1? MWLTRW5ITVJ?
CHP-212 MmP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrXToVKSzVyPUKuO|Uhdk1? MV;TRW5ITVJ?
GI-1 M134eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;Mb3ZMUUN3ME2yMlc3KG6P MmPKV2FPT0WU
HCC1806 NX;6OYViT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jUN2lEPTB;Mj65NUBvVQ>? M1m4NnNCVkeHUh?=
HLE NI\4eJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LJOmlEPTB;MzDuUS=> NIXoeYNUSU6JRWK=
HSC-2 MoHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPnbHZKSzVyPUOuNFMhdk1? NHG5dm9USU6JRWK=
DMS-273 Mni0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjNbVVKSzVyPUOuNFchdk1? MojLV2FPT0WU
DU-4475 NFfOSG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mon2TWM2OD1|LkG0JI5O NXzicJdjW0GQR1XS
LXF-289 M1y3Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rxcGlEPTB;Mz6zNUBvVQ>? NX\lTpZFW0GQR1XS
PANC-03-27 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHT0fpNKSzVyPUOuOVEhdk1? Mn;kV2FPT0WU
GAMG NFOxNotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M376fGlEPTB;Mz63OEBvVQ>? MnuwV2FPT0WU
NCI-H522 MkfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzLZZlKSzVyPUSuN|Qhdk1? MWTTRW5ITVJ?
SW626 M2\lNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3K1[mlEPTB;ND60OkBvVQ>? MojsV2FPT0WU
HT-144 M1zFUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInIWYNKSzVyPUSuPVIhdk1? NU\G[Xk{W0GQR1XS
MEL-HO NH;qOFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHKOGt6UUN3ME21MlE3KG6P MYfTRW5ITVJ?
BE-13 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjMTWM2OD13LkKxJI5O NVLUcWxEW0GQR1XS
VA-ES-BJ MmLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnGWXdZUUN3ME21MlI3KG6P NY[zXI5RW0GQR1XS
NCI-H441 M{PJVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\ETWlEPTB;NT62JI5O MkLlV2FPT0WU
KP-4 M2DLW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITHW|RKSzVyPUWuOlEhdk1? MnLaV2FPT0WU
LoVo MlX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPoVVI5UUN3ME21MlcyKG6P M1PBOnNCVkeHUh?=
HT-1080 NEPrcXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rze2lEPTB;NT64N{BvVQ>? M4\2ZXNCVkeHUh?=
GB-1 M3XVOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkT3TWM2OD13Lki0JI5O NXzm[VZ[W0GQR1XS
IA-LM NW[5V3ZFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnzbGZ6UUN3ME21MlkyKG6P NVzVco01W0GQR1XS
8-MG-BA MoXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnryTWM2OD13LkmzJI5O NIXWOINUSU6JRWK=
SK-HEP-1 NVP6[nN{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHEPWZZUUN3ME22MlE1KG6P NIr4TllUSU6JRWK=
697 MljhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXOzOVl[UUN3ME22MlI2KG6P MYnTRW5ITVJ?
KYSE-450 NWjIVWNOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3vTWM2OD14LkOyJI5O NYPYN5RzW0GQR1XS
HCC2998 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTZwM{Sgcm0> NILqUJJUSU6JRWK=
HD-MY-Z NIrDe3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLSTWM2OD14Lk[4JI5O MVrTRW5ITVJ?
OS-RC-2 NW\DNJpZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LTOmlEPTB;Nj62PEBvVQ>? NEHLWFhUSU6JRWK=
SF126 NVLuR45oT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnmWJFiUUN3ME23MlA2KG6P Mn76V2FPT0WU
Ca-Ski NEHDfmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTdwMEmgcm0> M3:5NHNCVkeHUh?=
NCI-H358 NHPoUYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvkTWM2OD15LkG2JI5O M1nNSHNCVkeHUh?=
J82 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TYWmlEPTB;Nz60NUBvVQ>? NV\SdmtiW0GQR1XS
NCI-H2342 NID6SGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfZNmREUUN3ME23MlY{KG6P MV\TRW5ITVJ?
OVCAR-8 M4Wxbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fHfmlEPTB;Nz65JI5O MXHTRW5ITVJ?
TE-8 NFz5NFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;VR2pHUUN3ME24JI5O MWLTRW5ITVJ?
ETK-1 M{P4bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTBbWRkUUN3ME24MlA5KG6P NHHsc|BUSU6JRWK=
HAL-01 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRThwMjDuUS=> M2fJZ3NCVkeHUh?=
KYSE-150 NVrGe496T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITQVZRKSzVyPUiuOFchdk1? M3Gyd3NCVkeHUh?=
NCI-H810 MlzwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRThwNU[gcm0> MkXGV2FPT0WU
ONS-76 NEOwV4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jrUWlEPTB;OD62PEBvVQ>? M3rhRXNCVkeHUh?=
NMC-G1 MlvyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HMdmlEPTB;OD63OkBvVQ>? NV32S25DW0GQR1XS
C3A Mn7sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\6dYJKSzVyPUiuPFQhdk1? MoLqV2FPT0WU
PA-1 M3rMcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRThwOUmgcm0> NVXWR5l[W0GQR1XS
SH-4 NXrzRlZZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\OUlJKSzVyPUmuNFIhdk1? M3z1dXNCVkeHUh?=
EFO-27 MnHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE[1Z5NKSzVyPUmuNFUhdk1? NGP4XY5USU6JRWK=
CAPAN-1 NVi2fm9rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvVdYd[UUN3ME25MlI{KG6P NVyxO4JNW0GQR1XS
DU-145 Mmi0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLQZVZKSzVyPUmuNlkhdk1? NXHvdnVCW0GQR1XS
A101D MoTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDTTJNIUUN3ME25MlM4KG6P NHnqOHhUSU6JRWK=
ST486 NV;Vdm1iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUf6dINMUUN3ME25MlQyKG6P NETER4dUSU6JRWK=
NCI-H1437 MlzZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;CWm5KSzVyPUmuOFIhdk1? M{XLPHNCVkeHUh?=
HGC-27 M2L6fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWT0[5NlUUN3ME25MlYhdk1? NYD5cHRpW0GQR1XS
8305C NVPQXHZwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PkVGlEPTB;OT62OEBvVQ>? M1P1eXNCVkeHUh?=
OCUB-M Mnr5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fhb2lEPTB;MUCuNFMhdk1? Mm\0V2FPT0WU
COLO-679 M3XYeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NECxXZJKSzVyPUGwMlA4KG6P NIrSV5dUSU6JRWK=
Detroit562 NV;EXXVpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDvS41KSzVyPUGwMlQzKG6P MkfkV2FPT0WU
A204 NHe4fXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3P2W2lEPTB;MUGuNVYhdk1? M13KWHNCVkeHUh?=
NCI-H1734 MlnRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;6TWM2OD1zMT6yPUBvVQ>? MWrTRW5ITVJ?
MC-CAR MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVL2enRDUUN3ME2xNU42QCCwTR?= NGrCZnJUSU6JRWK=
NCI-H2170 M{\2emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTFzLkm3JI5O MnzuV2FPT0WU
NCI-SNU-5 Mmf2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrBTWM2OD1zMj6xN{BvVQ>? MYDTRW5ITVJ?
HCE-T NH3LNG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnDcYs2UUN3ME2xNk41OiCwTR?= NH;tc2dUSU6JRWK=
KYSE-180 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLkPWF{UUN3ME2xNk45OSCwTR?= NW\KU4xVW0GQR1XS
C8166 NV7KTIZlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTF|LkC4JI5O MWPTRW5ITVJ?
NCI-H460 NGe3WVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTF|LkW0JI5O NEjxR2pUSU6JRWK=
SNU-449 NYTvZWxTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33yRmlEPTB;MUOuO|chdk1? MnXYV2FPT0WU
MDA-MB-468 NGK1VoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PCVGlEPTB;MUSuNVIhdk1? NWjQSoRSW0GQR1XS
COR-L23 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fEUmlEPTB;MUSuNVMhdk1? NIfNSYpUSU6JRWK=
CTV-1 NWW2fFF2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTF2LkG0JI5O MUDTRW5ITVJ?
BL-41 NVnMZlJuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTF2LkO3JI5O MXzTRW5ITVJ?
IGR-1 NH\PSmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHvTWM2OD1zND60NkBvVQ>? M13SfXNCVkeHUh?=
TK10 NVW4e3h[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TaeGlEPTB;MUSuOFkhdk1? Ml7XV2FPT0WU
REH NEP1XppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTieYlNUUN3ME2xOE42OSCwTR?= NWPzc4FvW0GQR1XS
LU-139 NHPJSGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXFTWM2OD1zND61PUBvVQ>? NF3PfVBUSU6JRWK=
KP-N-YS MnzpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnmWnZFUUN3ME2xOE46PyCwTR?= MWHTRW5ITVJ?
PANC-10-05 NGm5bXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjiTWM2OD1zNT6zPEBvVQ>? MYfTRW5ITVJ?
HL-60 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTF3Lk[5JI5O NUDmZW9EW0GQR1XS
T84 Ml;KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NED1fYtKSzVyPUG1Mlk3KG6P MmHpV2FPT0WU
RPMI-8226 M4fQXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELJVppKSzVyPUG2MlAzKG6P M4PJSXNCVkeHUh?=
UM-UC-3 NFW3emtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\0TWM2OD1zNj6xOkBvVQ>? MVjTRW5ITVJ?
TE-10 NIW1S2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jMOGlEPTB;MU[uNlEhdk1? MlTtV2FPT0WU
CAL-148 M2rDdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTF5LkKzJI5O NGnuPW1USU6JRWK=
BV-173 NHz5R4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfJO5ZKSzVyPUG3MlI4KG6P M37RfXNCVkeHUh?=
Calu-3 NYnMTJl1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTOTWM2OD1zNz6yPUBvVQ>? MWHTRW5ITVJ?
RPMI-2650 NVLGbplIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXFR25tUUN3ME2xO{42QSCwTR?= NHy4ZlJUSU6JRWK=
MKN45 M2nvXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3T1TGlEPTB;MUeuO|Mhdk1? MlriV2FPT0WU
NUGC-3 M{LjWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17RPWlEPTB;MUiuN|Qhdk1? NXOwS|JLW0GQR1XS
NCI-H520 MmjLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PadGlEPTB;MUiuO|chdk1? NULCTW01W0GQR1XS
CCRF-CEM MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3hbIRKSzVyPUG4Mlg2KG6P NIPmSZVUSU6JRWK=
NCI-H2405 MnizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXDTWM2OD1zOT6xJI5O M4jaV3NCVkeHUh?=
ES7 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTOToRKSzVyPUG5Mlc3KG6P NUHlUZVZW0GQR1XS
BPH-1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\xUGlEPTB;MkCuNlghdk1? NYLtS|hCW0GQR1XS
SAS M4LGeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DhNmlEPTB;MkCuOUBvVQ>? NWC1XIRIW0GQR1XS
HuCCT1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrxTWM2OD1{MD61PEBvVQ>? NGX4VItUSU6JRWK=
LOUCY MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\YTWM2OD1{MD62OkBvVQ>? MXjTRW5ITVJ?
NCI-H292 MlPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF6xZYNKSzVyPUKwMlc6KG6P NFvFelBUSU6JRWK=
G-361 NWKzc4twT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfnblRKSzVyPUKxMlA4KG6P MlXZV2FPT0WU
M059J MmTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTJzLkC4JI5O MW\TRW5ITVJ?
NCI-H1651 NF7LSlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vCTmlEPTB;MkGuNVEhdk1? M3rn[HNCVkeHUh?=
KALS-1 NUfzR4JrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlG1TWM2OD1{MT6zPUBvVQ>? NVjp[JQ5W0GQR1XS
DJM-1 NFX0Zo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTtOWtTUUN3ME2yNU42QSCwTR?= MlLzV2FPT0WU
AU565 M{XHPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfnTWM2OD1{MT64N{BvVQ>? NXLoPWtRW0GQR1XS
HCC38 MmrOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTJzLkm1JI5O M2mwWHNCVkeHUh?=
U251 M4f3bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTJ{LkK3JI5O MVrTRW5ITVJ?
ABC-1 M1fCfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXufnFUUUN3ME2yNk43PSCwTR?= NGPvTHFUSU6JRWK=
SK-NEP-1 NV;UNY9rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHPbHhMUUN3ME2yNk46OyCwTR?= NYrGS|FkW0GQR1XS
CESS Mm\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTWTWM2OD1{Mz6xPUBvVQ>? MVTTRW5ITVJ?
MIA-PaCa-2 M2DlNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jpS2lEPTB;MkOuN|Yhdk1? Mn20V2FPT0WU
SUP-T1 MmLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTJ|LkS3JI5O NXfwPG9tW0GQR1XS
L-428 M{HR[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PUSGlEPTB;MkOuOlIhdk1? NUHzVmJIW0GQR1XS
SW954 NXn1bW5uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\pd2lEPTB;MkOuOlghdk1? MXPTRW5ITVJ?
HO-1-N-1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfMTWM2OD1{Mz63O{BvVQ>? MXfTRW5ITVJ?
CHP-126 M1rtNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXQTWM2OD1{ND6xOEBvVQ>? NIHnUGhUSU6JRWK=
HMV-II Mk\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\DbWlEPTB;MkSuN|Qhdk1? MXjTRW5ITVJ?
NB10 NEfFNlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXZTWM2OD1{ND6zO{BvVQ>? M{TWRnNCVkeHUh?=
A172 M4DhUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjnOVJmUUN3ME2yOE44OSCwTR?= MXTTRW5ITVJ?
MONO-MAC-6 NFPmc5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;UcGlEPTB;MkSuPFQhdk1? MX3TRW5ITVJ?
NCI-H1650 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{f2XmlEPTB;MkWuOEBvVQ>? MknoV2FPT0WU
NH-12 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3WTWM2OD1{NT61JI5O MWDTRW5ITVJ?
ML-2 NXzyTpJkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTJ3Lke0JI5O MWTTRW5ITVJ?
MZ2-MEL M4TNTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTJ4LkKyJI5O NXTzW3ZYW0GQR1XS
COLO-684 Mkm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULYN4I3UUN3ME2yOk41OSCwTR?= NVLrUZdNW0GQR1XS
HuP-T4 NW\RRmh5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTJ5LkOgcm0> MXzTRW5ITVJ?
SW837 NUfGRlhOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLMTWM2OD1{Nz62NkBvVQ>? NUL0cVk4W0GQR1XS
MDA-MB-231 MljzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LyfGlEPTB;MkeuO|ghdk1? NFPGXYJUSU6JRWK=
KYSE-140 NWGxZoVST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7rPGZYUUN3ME2yO{46OSCwTR?= M17yNnNCVkeHUh?=
NOMO-1 M3\zOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLvUJhGUUN3ME2yPE43QCCwTR?= MVPTRW5ITVJ?
GP5d MkDJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDiTWM2OD1{OD63NkBvVQ>? MUnTRW5ITVJ?
COR-L105 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2Hy[mlEPTB;MkmuOFIhdk1? MmrPV2FPT0WU
LS-411N NEHIb3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHHOXRKSzVyPUK5Mlg5KG6P NXnIN|Q6W0GQR1XS
NY NFXheGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPKTXJKSzVyPUOwMlE5KG6P MXTTRW5ITVJ?
NCI-H2030 M1rDd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\TTWM2OD1|MD60OUBvVQ>? NUmzPVdWW0GQR1XS
CCF-STTG1 NEXieVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3L0TmlEPTB;M{GuOFIhdk1? NV61PYtnW0GQR1XS
NCI-H1703 NXO2cIlvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn2yTWM2OD1|MT63PEBvVQ>? NV;FW4tbW0GQR1XS
TUR NWnmW4JHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrnco1HUUN3ME2zNk4xOyCwTR?= MUXTRW5ITVJ?
NOS-1 MkfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDQbGJ3UUN3ME2zNk41PCCwTR?= M3vkbHNCVkeHUh?=
A2058 Mn3aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvyWodjUUN3ME2zNk45OyCwTR?= NUPwdVNEW0GQR1XS
LCLC-103H MmPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M165WGlEPTB;M{OuNlUhdk1? M{DO[nNCVkeHUh?=
NCI-H510A NXHidHBtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVG5ZlhMUUN3ME2zN{4zPyCwTR?= MmX4V2FPT0WU
BC-1 M{DTVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTN|Lke3JI5O MoW2V2FPT0WU
SK-CO-1 NVrEN|FqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDaTWM2OD1|ND6wNUBvVQ>? MmHuV2FPT0WU
A673 NYD5ZpViT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTN2LkG3JI5O MWLTRW5ITVJ?
VM-CUB-1 M3zvfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zJNWlEPTB;M{SuOlkhdk1? MVLTRW5ITVJ?
HH MmrsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTN3LkC2JI5O Mn7YV2FPT0WU
CAL-27 NGfiZZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3xTWM2OD1|NT6xOkBvVQ>? MkGwV2FPT0WU
NEC8 M1PwWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTN3LkO3JI5O MX7TRW5ITVJ?
BxPC-3 NE\5Vo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnMUIdKSzVyPUO2MlkyKG6P M3jz[nNCVkeHUh?=
SNB75 NXjyeVViT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2[1N2lEPTB;M{euNlQhdk1? NYnaRlZrW0GQR1XS
NB13 NFrtNYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHn6XJVKSzVyPUO4MlI{KG6P Mn7SV2FPT0WU
SK-OV-3 MoTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknoTWM2OD1|OD63OEBvVQ>? NH7JcVJUSU6JRWK=
ME-180 NV\VT|duT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTN6Lkigcm0> MnrTV2FPT0WU
JiyoyeP-2003 Mn\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jPN2lEPTB;M{muN|ghdk1? NFPYfZRUSU6JRWK=
LU-134-A MmnVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnhN2xKSzVyPUSwMlAzKG6P M3PWcXNCVkeHUh?=
LS-123 NFLnc5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFi0eWNKSzVyPUSwMlI5KG6P NF7uT4NUSU6JRWK=
COLO-800 NFvZ[G9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnW3TWM2OD12MD61OkBvVQ>? MWjTRW5ITVJ?
LB831-BLC MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfHTWM2OD12MT64OUBvVQ>? MYTTRW5ITVJ?
NCI-H747 MlHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXLUI5OUUN3ME20Nk4zQCCwTR?= MXrTRW5ITVJ?
MZ7-mel MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWi4OpZRUUN3ME20Nk43PiCwTR?= M4LTfXNCVkeHUh?=
GT3TKB NH7JcYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTR{LkeyJI5O M{fDTnNCVkeHUh?=
MOLT-16 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn[yTWM2OD12Mz6wOUBvVQ>? NV\5cY9SW0GQR1XS
23132-87 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHxTWM2OD12Mz6wOUBvVQ>? MnfVV2FPT0WU
PF-382 NEjQe|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjWSIxjUUN3ME20OE4zOiCwTR?= NI\GSYlUSU6JRWK=
ES3 NYnYSldoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rQTGlEPTB;NESuOkBvVQ>? M4m0UnNCVkeHUh?=
SW756 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXaTWM2OD12NT6xOEBvVQ>? M2fES3NCVkeHUh?=

多くの細胞株試験データを見る場合、クリックしてください

体内試験 Gemcitabine combined with C225 results in growth inhibition, tumor regression, and abrogation of metastasis in L3.6pl tumors established in the pancreas of nude mice. Gemcitabine treatment alone reduces median tumor volume from 538 to 152 mm3. Gemcitabine reduces the production of vascular endothelial growth factor and interleukin 8 in gemcitabine-treated tumors. [2] Gemcitabine is able to dramatically and specifically reduces the number of myeloid suppressor cells found in the spleens of animals bearing large tumors with no significant reductions in CD4(+) T cells, CD8(+) T cells, NK cells, macrophages, or B cells. [4] Gemcitabine combined with curcumin shows significant reductions in volume (P = 0.008 versus control; P = 0.036 versus gemcitabine alone), Ki-67 proliferation index (P = 0.030 versus control), NF-kappaB activation, and expression of NF-kappaB-regulated gene products (cyclin D1, c-myc, Bcl-2, Bcl-xL, cellular inhibitor of apoptosis protein-1, cyclooxygenase-2, matrix metalloproteinase, and vascular endothelial growth factor) compared with tumors from control mice treated with olive oil only. Gemcitabine combined with Curcumin is also highly effective in suppressing angiogenesis as indicated by a decrease in CD31(+) microvessel density. [5]

お薦めの試験操作(参考用のみ)

溶解度 (25°C)

体外 DMSO 52 mg/mL (197.56 mM)
Water 52 mg/mL warmed (197.56 mM)
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます:
water (warmed)
混合させたのち直ちに使用することを推奨します。
52mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 263.2
化学式

C9H11F2N3O4

CAS No. 95058-81-4
保管
in solvent
別名 LY-188011, NSC 613327

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02181634 Active, not recruiting Cholangiocarcinoma PrECOG, LLC.|Celgene Corporation December 9, 2014 Phase 2
NCT01535924 Recruiting Adult Lymphocyte Depletion Hodgkin Lymphoma|Adult Lymphocyte Predominant Hodgkin Lymphoma|Adult Mixed Cellularity Hodgkin Lymphoma|Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma|Adult Nodular Sclerosis Hodgkin Lymphoma|Recurrent Adult Hodgkin Lymphoma Kristie Blum|Ohio State University Comprehensive Cancer Center February 9, 2012 Phase 1|Phase 2
NCT01285037 Recruiting Cancer Eli Lilly and Company September 9, 2009 Phase 1
NCT01828736 Completed Recurrent Bladder Cancer|Stage IV Bladder Cancer|Transitional Cell Carcinoma of the Bladder Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie|Roche Pharma AG February 9, 2004 Phase 2
NCT01352962 Active, not recruiting Urethral Neoplasms|Neoplasms, Urethral|Ureter Cancer|Cancer of the Urethra|Urethral Cancer National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) April 5, 2011 Phase 1
NCT03027284 Recruiting Advanced Cancer|Metastatic Cancer|Biliary Tract Carcinoma|Cholangiocarcinoma|Gall Bladder Carcinoma|Solid Tumor|Non-Hodgkins Lymphoma Eli Lilly and Company February 3, 2017 Phase 1

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問(FAQ)

  • 質問1:

    What is the difference between gemcitabine(S1714 ) and Gemcitabine HCl (S1149)?

  • 回答:

    Gemcitabine HCl is the HCl salt form of Gemcitabine. They have the same biological activities. The free base(S1714) dissolves better in DMSO, and the hydrochloride (S1149) dissolves better in water.

DNA/RNA Synthesisシグナル伝達経路

相関DNA/RNA Synthesis製品

Tags: Gemcitabine を買う | Gemcitabine ic50 | Gemcitabine 供給者 | Gemcitabine を購入する | Gemcitabine 費用 | Gemcitabine 生産者 | オーダーGemcitabine | Gemcitabine 化学構造 | Gemcitabine 分子量 | Gemcitabine 代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID